论文部分内容阅读
目的探讨阿奇霉素和头孢三代菌素联用治疗小儿支原体肺炎的临床疗效。方法选取110例支原体肺炎患儿,随机分为实验组和对照组,实验组患儿给予阿奇霉素和头孢三代菌素联用治疗,对照组患儿仅给予阿奇霉素治疗,比较两组患儿的临床疗效、临床症状消失时间及不良反应发生情况。结果实验组患儿的临床疗效总有效率为92.73%,较对照组患儿(81.82%)显著提高,其中实验组患儿的显效率为54.55%,而对照组患儿的显效率仅为32.73%,咳嗽时间、退热时间及肺部啰音消失时间较对照组患儿均显著缩短,不良反应发生率为5.45%,较对照组患儿(20.00%)显著降低,差异有统计学意义(P<0.05)。结论阿奇霉素和头孢三代菌素联用治疗小儿支原体肺炎能够提高其治疗的临床疗效,改善患儿的临床症状,缩短临床症状消失时间,提高患儿的生命质量,同时降低不良反应发生率,确保治疗的安全性,值得在临床儿科推广。
Objective To investigate the clinical efficacy of azithromycin and cefuroxime axetil in treating children with mycoplasma pneumonia. Methods A total of 110 children with mycoplasmal pneumonia were selected and randomly divided into experimental group and control group. In the experimental group, azithromycin and ceftriaxone were given to the children in the experimental group, azithromycin alone was given to the control group, and the clinical efficacy was compared between the two groups , The disappearance of clinical symptoms and the occurrence of adverse reactions. Results The total effective rate of the experimental group was 92.73%, which was significantly higher than that of the control group (81.82%). The effective rate of the experimental group was 54.55%, while the effective rate of the control group was only 32.73 %, Cough time, fever time and pulmonary rales disappeared significantly shorter than the control group, the incidence of adverse reactions was 5.45%, compared with the control group (20.00%) was significantly lower, the difference was statistically significant ( P <0.05). Conclusion Azithromycin and ceftriaxone combined treatment of children with mycoplasma pneumonia can improve the clinical efficacy of treatment, improve clinical symptoms, shorten the disappearance of clinical symptoms and improve the quality of life of children, while reducing the incidence of adverse reactions to ensure treatment The safety, it is worth in the clinical pediatric promotion.